Correction of morphofunctional disorders of the cardiovascular system with asialized erythropoietin and arginase II selective inhibitors KUD 974 and KUD 259 in experimental preeclampsia
Authors:
- Tatyana I. LoktevaTLTatyana I. Lokteva
- Il’ya S. RozhkovIRIl’ya S. Rozhkov
- Vladimir V. GureevVGVladimir V. Gureev
- Anastasia V. GureevaAGAnastasia V. Gureeva
- Marija A. ZatolokinaMZMarija A. Zatolokina
- Elena V. AvdeevaEAElena V. Avdeeva
- Lyudmila A. ZhilinkovaLZLyudmila A. Zhilinkova
- Elizoveta O. YarcevaEYElizoveta O. Yarceva
Open Access
- 20 March 2020
- journal article
- research article
- Published by Belgorod National Research University in Research Results in Pharmacology
- Vol. 6 (1) , 29-40
Abstract
Introduction: Preeclampsia remains one of the most common causes of maternal and perinatal mortality worldwide. A significant role in the pathogenesis of this pathology is assigned to placental ischemia and endothelial dysfunction. Therefore, the aim of the present study was to study the effectiveness of asialized erythropoietin and arginase II selective inhibitors: KUD-259 and KUD-974 in the correction of morphofunctional disorders of the cardiovascular system in experimental preeclampsia. Materials and methods: The study was performed in 260 female Wistar rats, each weighing 250–300 g. An ADMA-like preeclampsia was reproduced in the experiment. To assess the emerging morphofunctional disorders, the following parameters were used: blood pressure, coefficient of endothelial dysfunction, microcirculation in the placenta, proteinuria, fluid content in the omentum, concentration of terminal metabolites in the blood plasma, and morphometric parameters of fetuses. Results and discussion: The administration of arginase II selective inhibitor KUD-974 in combination with asialized erythropoietin leads to a pronounced correction of emerging changes: a decrease in systolic and diastolic blood pressure in 1.5 and 1.7 times, a decrease in proteinuria in 3.6 times and a decrease in fluid content in the omentum. When arginase II selective inhibitor KUD 974 and asialized erythropoietin are used with methyldopa, the positive effects of the former are enhanced. Conclusion: Arginase II selective inhibitors KUD-259 and KUD-974 and asialized erythropoietin have a pronounced positive effect on the correction of morphofunctional disorders in animals with ADMA-like preeclampsia.Keywords
This publication has 30 references indexed in Scilit:
- Pregnancy-Related Acute Kidney Injury in PreeclampsiaHypertension, 2019
- Oxidative Stress in Preeclampsia and Placental DiseasesInternational Journal of Molecular Sciences, 2018
- Carbon Monoxide Releasing Molecules Blunt Placental Ischemia-Induced HypertensionAmerican Journal of Hypertension, 2017
- Global, regional, and national levels and trends in maternal mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Maternal Mortality Estimation Inter-Agency GroupThe Lancet, 2016
- NEW APPROACHES OF MORFOFUNKTIONAL PHARMACOLOGICAL CORRECTION OF VIOLATIONS OF CARDIOVASCULAR SYSTEM IN EXPERIMENTAL PREECLAMPSIARESEARCH RESULT Pharmacology and Clinical Pharmacology, 2016
- CORRECTION OF ADMA-INDUCED PREECLAMPSIA WITH THE USE OF PHOSPHODIESTERASE 5 AND SELECTIVE INHIBITOR OF ARGINASE II ZB49-0010Research Result. MEDICINE AND PHARMACY SERIES, 2015
- Global and regional estimates of preeclampsia and eclampsia: a systematic reviewEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2013
- Enhancement of ventricular-subventricular zone-derived neurogenesis and oligodendrogenesis by erythropoietin and its derivativesFrontiers in Cellular Neuroscience, 2013
- A single injection of liposomal asialo-erythropoietin improves motor function deficit caused by cerebral ischemia/reperfusionInternational Journal of Pharmaceutics, 2012
- Review of the Role of Erythropoietin in Critical Leg IschemiaAngiology, 2010